… NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through … addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional $11,250,000 of … proceeds from the offering to fund ongoing research and development activities and for working capital and other …
… ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares … addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the offering … existing cash and cash equivalents, to advance clinical development of its product candidates, to progress its other …
… oligonucleotide QR-110 for treatment of inherited retinal dystrophy in adults and children with LCA10 Presenter : David … Poster title: Structure-based computational approach for optimizing oligonucleotides for A-to-I editing Poster #: 29 … orphan drug designation in the United States and the European Union and received fast-track designation by the …
… 1b safety, tolerability and exploratory efficacy trial. Top-line data to be reported in mid-2017 Top-line data from a … of QR-010. A full study presentation is planned for the European Cystic Fibrosis Society Conference in June 2017. … QR-010 is designed to be self-administered via an optimized eFlow® Nebulizer (PARI Pharma GmbH). eFlow® is a …
… - Nucleic Acids . LCA10 is a severe inherited retinal dystrophy associated with mutations in the CEP290 gene. … process by which QR-110 was identified as a potentially optimal therapeutic candidate using a patient-derived retinal … suggest the pharmacodynamic, pharmacokinetic and safety properties make QR-110 a promising candidate for the …
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Mas